Yazar "Ekinci, Omer" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Brentuximab Vedotin Monotherapy in Relapsed/Refractory T Cell Lymphoma Setting-Real Life Data
    (Hitit Üniverstesi Tıp Fakültesi, 23.07.2024) Darçın, Tahir; Serın, Istemi; Ugur, Mehmet Can; Ekinci, Omer; Hindilerden, Ipek Yonal; Akpınar, Seval; Hacibekiroglu, Tuba; Demircioğlu, Sinan; Gültürk, Emine; Albayrak, Murat; Aydogdu, Ismet; Dal, Mehmet Sınan; Doğu, Mehmet Hilmi; Namdaroglu, Sinem; Doğan, Ali; Nalcaci, Meliha; Turgut, Burhan; Başcı, Semih; Altuntas, Fevzi
    Objective: We present data of patients with relapsed/ refractory T cell lymphomas treated with brentuximab vedotin (BV) in real-world practice. Material and Method: This study is an observational, multi-center, retrospective study. The data of patients (n=17) treated with BV alone from January 2014 until July 2020 in thirteen centers from Turkey were collected. Results: Bv was given as salvage chemotherapy to 17 patients with median age of 53. Nine (52.9%) patients had diagnosis of peripheral T cell lymphoma, not otherwise specified; 8 (47.1%) patients had anaplastic large T cell lymphoma. The median follow-up of the cohort was 20 months. Nine (52.9%) patients had complete response, 5 (29.5%) had partial response, 3 (17.6%) had progressive disease. The safety results aligned with the established profile of BV, included 2 pneumonia and 1 thrombocytopenia with grade 4. The median progression free survival of the cohort was 10 months. BV cycle and response to BV therapy were found to have an effect on the univariate analysis. Conclusion: In patients with relapsed/ refractory T cell lymphomas, BV seems to have convincing antitumor activity with favorable safety profile.
  • Küçük Resim Yok
    Öğe
    A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera
    (Galenos Publ House, 2023) Serin, Istemi; Dogu, Mehmet Hilmi; Ekinci, Omer; Cagliyan, Gulsum Akgun; Basturk, Abdulkadir; Aras, Merih Reis; Demircioglu, Sinan
    Introduction: Ruxolitinib is a small -molecule inhibitor of the JAK1/2 pathway. This study aimed to reveal the results and side-effect profile of the use of ruxolitinib as a treatment option in polycythemia vera (PV). Methods: A total of 34 patients with PV from 18 different centers were included in the study. The evaluation of the response under treatment with ruxolitinib was determined as a reduction in spleen volume (splenomegaly size: >= 35%) by imaging and control of hematocrit levels (<= 45%) compared to baseline. Results: While the number of patients in which a reduction in spleen volume and hematocrit control was achieved was 19 (55.9%) at 3 months of treatment, it was 21 (61.8%) at 6 months. Additionally, while the number of side effects was negatively correlated with the reduction in spleen volume (Spearman's rho: -0.365, p=0.034), a decrease in the hematocrit level was positively correlated (Spearman's rho: 0.75, p=0.029). Those without a reduction in spleen volume experienced more constipation (chi-square: 5.988, Fisher's exact test: p=0.033). Conclusion: This study shed light on the use of ruxolitinib in PV and the importance of splenomegaly on studies planned with larger patient groups.